ESTRO 2024 - Abstract Book

S1846

Clinical - Mixed sites, palliation

ESTRO 2024

Our clinical experience with the extended FAST-METS cohort demonstrated successful treatments with reduced treatment times compared to the initial cohort. The FAST-METS protocol is currently being implemented as a standard procedure at multiple sites within our department. This implementation enhances accessibility to this workflow, and also improves patient comfort.

Keywords: Online adaptive RT, same-day treatment, oART

References:

[1] Nelissen KJ, Versteijne E, Senan S, Rijksen B, Admiraal M, Visser J, Barink S, de la Fuente AL, Hoffmans D, Slotman BJ, Verbakel WF. Same-day adaptive palliative radiotherapy without prior CT simulation: Early outcomes in the FAST METS study. Radiotherapy and Oncology. 2023 May 1;182:109538. https://doi.org/10.1016/j.radonc.2023.109538 [2] Kejda A, Quinn A, Wong S, Lowe T, Fent I, Gargett M, Roderick S, Grimberg K, Bergamin S, Eade T, Booth J. Evaluation of the clinical feasibility of cone-beam computed tomography guided online adaption for simulation-free palliative radiotherapy. Physics and Imaging in Radiation Oncology. 2023 Oct 1;28:100490. https://doi.org/10.1016/j.phro.2023.100490

409

Proffered Paper

Quality of Life in the SCORAD Trial of Spinal Cord Compression (ISRCTN97555949/ISRCTN97108008)

Peter Hoskin 1,2 , Krystyna Reczko 3 , Memuna Rashid 3 , Andres Lopes 3 , Allan Hackshaw 3

1 Mount Vernon Cancer Centre, Cancer Centre, Northwood, United Kingdom. 2 University of Manchester, Division of Cancer Sciences, Manchester, United Kingdom. 3 CRUK & UCL Cancer Trials Centre, CTU, London, United Kingdom

Purpose/Objective:

Metastatic spinal cord compression (MSCC) has a major impact on quality of life but objective data is sparse. SCORAD randomised 686 patients with MSCC and compared two doses of radiotherapy: 8Gy single fraction and 20Gy in 5 fractions. No clinically important differences were found between the two study arms and there was a median overall survival of only 13 weeks.. Detailed quality of life data and preferred place of care was obtained in the trial and is reported here.

Material/Methods:

Health Related Quality of Life (HRQoL) data was collected from 590 patients in the trial at baseline and ≥1 later time point using EORTC QLQ-C30 supplemented with the QLU-C10D a preference-based measure derived from 10 of the 15 dimensions of QLQ-C30 which was used to produce UK-validated utility weights. Data was reported by patients at weeks 1, 4, 8, and 12 post-randomisation. Baseline data was complete in 98% of participants.